DOI QR코드

DOI QR Code

Association between the TGFBR2 G-875A Polymorphism and Cancer Risk: Evidence from a Meta-analysis

  • Huang, Yong-Sheng (Institute of Basic Medical Sciences and School of Basic Medicine, Peking Union Medical College and Chinese Academy of Medical Sciences) ;
  • Zhong, Yu (The State Key Laboratory of Genetic Engineering, Institute of Genetics, School of Life Science, Fudan University) ;
  • Yu, Long (The State Key Laboratory of Genetic Engineering, Institute of Genetics, School of Life Science, Fudan University) ;
  • Wang, Lin (Institute of Basic Medical Sciences and School of Basic Medicine, Peking Union Medical College and Chinese Academy of Medical Sciences)
  • 발행 : 2014.11.06

초록

Disrupted transforming growth factor-${\beta}$ (TGF-${\beta}$) signaling is involved in the development of various types of cancer and the TGF-${\beta}$ receptor II (TGFBR2) is a key mediator of TGF-${\beta}$ growth inhibitory signals. It is reported that the G-875A polymorphism in TGFBR2 is implicated in risk of various cancers. However, results for the association between this polymorphism and cancer remain conflicting. To derive a more precise estimation, a meta-analysis of 3,808 cases and 4,489 controls from nine published case-control studies was performed. Our analysis indicated that G-875A is associated with a trend of decreased cancer risk for allele A versus(vs.) allele G [odds ratio (OR) =0.64, 95% confidence intervals (CI): 0.55-0.74], as well as for both dominant model [(A/A+G/A) vs. G/G, OR=0.76, 95% CI: 0.64-0.90] and recessive model [A/A vs. (G/G+G/A), OR=0.74, 95% CI: 0.59-0.93). However, larger scale primary studies are required to further evaluate the interaction of TGFBR2 G-875A polymorphism and cancer risk in specific cancer subtypes.

키워드

참고문헌

  1. Adorno M, Cordenonsi M, Montagner M, et al (2009). A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell, 137, 87-98. https://doi.org/10.1016/j.cell.2009.01.039
  2. Derynck R, Akhurst RJ, Balmain A (2001). TGF-beta signaling in tumor suppression and cancer progression. Nat Genet, 29, 117-29. https://doi.org/10.1038/ng1001-117
  3. Derynck R, Zhang YE (2003). Smad-dependent and Smadindependent pathways in TGF-beta family signalling. Nature, 425, 577-84. https://doi.org/10.1038/nature02006
  4. Guo W, Dong Z, Guo Y, et al (2012). Association of polymorphisms in transforming growth factor-beta receptors with susceptibility to gastric cardia adenocarcinoma. Mol Biol Rep, 39, 4301-9. https://doi.org/10.1007/s11033-011-1217-0
  5. Huang Y, Hao Y, Li B, et al (2011). Lack of significant association between TGF-beta1-590C/T polymorphism and breast cancer risk: a meta-analysis. Med Oncol, 28, 424-8. https://doi.org/10.1007/s12032-010-9491-6
  6. Huang Y, Li B, Qian J, et al (2010). TGF-beta1 29T/C polymorphism and breast cancer risk: a meta-analysis involving 25, 996 subjects. Breast Cancer Res Treat, 123, 863-8. https://doi.org/10.1007/s10549-010-0796-0
  7. Ikushima H, Miyazono K (2010). TGFbeta signalling: a complex web in cancer progression. Nat Rev Cancer, 10, 415-24. https://doi.org/10.1038/nrc2853
  8. Jin G, Deng Y, Miao R, et al (2008). TGFB1 and TGFBR2 functional polymorphisms and risk of esophageal squamous cell carcinoma: a case-control analysis in a Chinese population. J Cancer Res Clin Oncol, 134, 345-51. https://doi.org/10.1007/s00432-007-0290-1
  9. Jin G, Wang L, Chen W, et al (2007). Variant alleles of TGFB1 and TGFBR2 are associated with a decreased risk of gastric cancer in a Chinese population. Int J Cancer, 120, 1330-5. https://doi.org/10.1002/ijc.22443
  10. Jin Q, Hemminki K, Grzybowska E, et al (2004). Polymorphisms and haplotype structures in genes for transforming growth factor beta1 and its receptors in familial and unselected breast cancers. Int J Cancer, 112, 94-9. https://doi.org/10.1002/ijc.20370
  11. Li Z, Zhang LJ, Zhang HR, et al (2014). Tumor-derived transforming growth factor-beta is critical for tumor progression and evasion from immune surveillance. Asian Pac J Cancer Prev, 15, 5181-6. https://doi.org/10.7314/APJCP.2014.15.13.5181
  12. Liu Y, Lin XF, Lin CJ, et al (2012). Transforming growth factor beta-1 C-509T polymorphism and cancer risk: a metaanalysis of 55 case-control studies. Asian Pac J Cancer Prev, 13, 4683-8. https://doi.org/10.7314/APJCP.2012.13.9.4683
  13. Massague J (2008). TGFbeta in cancer. Cell, 134, 215-30. https://doi.org/10.1016/j.cell.2008.07.001
  14. Massague J (2012a). TGF-beta signaling in development and disease. FEBS Lett, 586, 1833. https://doi.org/10.1016/j.febslet.2012.05.030
  15. Massague J (2012b). TGFbeta signalling in context. Nat Rev Mol Cell Biol, 13, 616-30. https://doi.org/10.1038/nrm3434
  16. Schmierer B, Hill CS (2007). TGFbeta-SMAD signal transduction: molecular specificity and functional flexibility. Nat Rev Mol Cell Biol, 8, 970-82. https://doi.org/10.1038/nrm2297
  17. Seijo ER, Song H, Lynch MA, et al (2001). Identification of genetic alterations in the TGFbeta type II receptor gene promoter. Mutat Res, 483, 19-26. https://doi.org/10.1016/S0027-5107(01)00217-2
  18. Teixeira AL, Gomes M, Nogueira A, et al (2013). Improvement of a predictive model of castration-resistant prostate cancer: functional genetic variants in TGFbeta1 signaling pathway modulation. PLoS One, 8, 72419. https://doi.org/10.1371/journal.pone.0072419
  19. Wu MY, Hill CS (2009). Tgf-beta superfamily signaling in embryonic development and homeostasis. Dev Cell, 16, 329-43. https://doi.org/10.1016/j.devcel.2009.02.012
  20. Xu L, Zeng Z, Chen B, et al (2011). Association between the TGFB1 -509C/T and TGFBR2 -875A/G polymorphisms and gastric cancer: a case-control study. Oncol Lett, 2, 371-7.
  21. Zhang M, Guo L, Cheng Z, et al (2011). A functional polymorphism of TGFBR2 is associated with risk of breast cancer with ER (+), PR (+), ER (+)PR (+) and HER2 (-) expression in women. Oncol Lett, 2, 653-8.
  22. Zhou Y, Jin GF, Jiang GJ, et al (2007). Correlations of polymorphisms of TGFB1 and TGFBR2 genes to genetic susceptibility to gastric cancer. Ai Zheng, 26, 581-5.

피인용 문헌

  1. MicroRNA-19a promotes nasopharyngeal carcinoma by targeting transforming growth factor β receptor 2 vol.14, pp.2, 2017, https://doi.org/10.3892/etm.2017.4655